Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Navacaprant hydrochloride by Neumora Therapeutics for Bipolar II Disorder: Likelihood of Approval
Navacaprant hydrochloride is under clinical development by Neumora Therapeutics and currently in Phase II for Bipolar II Disorder. According to...
Risk adjusted net present value: What is the current valuation of Neumora Therapeutics's Navacaprant?
Navacaprant is a small molecule commercialized by Neumora Therapeutics, with a leading Phase III program in Major Depressive Disorder. According...
Navacaprant hydrochloride by Neumora Therapeutics for Bipolar Disorder (Manic Depression): Likelihood of Approval
Navacaprant hydrochloride is under clinical development by Neumora Therapeutics and currently in Phase II for Bipolar Disorder (Manic Depression). According...
NMRA-M4R by Neumora Therapeutics for Schizophrenia: Likelihood of Approval
NMRA-M4R is under clinical development by Neumora Therapeutics and currently in Phase I for Schizophrenia. According to GlobalData, Phase I...